Personalized Medicine Needs Personalized Advocacy To Advance, PhRMA Says
This article was originally published in The Pink Sheet Daily
CEO Castellani says message has to be specifically tailored to payers, patient advocates and regulators.
You may also be interested in...
Roundtable panelists, including the chair of the Patient Centered Outcomes Research Institute's communications committee, discuss the future of disseminating results of comparative effectiveness research.
Final package expected to be published in late summer following clearance by the administration.
Regulatory Workaround, Not Statutory Changes, Better For Personalized Medicine Development, FDA Commissioner Hamburg Says
FDA Commissioner Margaret Hamburg said that working within the current regulatory framework rather than seeking new statutory authority to address the development of drugs and accompanying diagnostic tests would be preferable to address personalized medicine questions at the agency